VERVE THERAPEUTICS INC (NASDAQ:VERV) - A High-Growth Biotech Stock Meeting Minervini's Criteria

VERVE THERAPEUTICS INC (NASDAQ:VERV) has been identified as a high-growth momentum stock that aligns with Mark Minervini's Trend Template strategy. The company, which focuses on gene-editing treatments for cardiovascular disease, demonstrates strong technical and fundamental characteristics that may appeal to growth-oriented investors.

Why VERV Fits Minervini’s Trend Template

The stock meets all key technical criteria outlined in Minervini’s strategy:

• Price Above Key Moving Averages:
  • Current price ($11.13) is well above the 50-day SMA ($6.77), 150-day SMA ($6.34), and 200-day SMA ($6.09).
  • The 50-day SMA is above both the 150-day and 200-day SMAs, confirming bullish momentum.
• Strong Relative Strength:
  • With a ChartMill Relative Strength (CRS) score of 98.3, VERV outperforms nearly all stocks in its sector.
• Price Near 52-Week High:
  • Trading within 2.4% of its 52-week high ($11.40), indicating sustained upward momentum.
• Trending Moving Averages:
  • The 150-day and 200-day SMAs are both rising, reinforcing long-term strength.

High-Growth Fundamentals

VERV’s financial metrics suggest accelerating growth, a key factor for momentum investors:

• Revenue Growth:
  • Quarterly revenue surged 479% year-over-year, with consistent beats on analyst estimates.
  • Full-year revenue growth stands at 175%, signaling strong commercial potential.
• Earnings Momentum:
  • EPS improved 40.7% in the latest quarter, with positive revisions for future earnings.
  • The company has beaten EPS estimates in all of the last four quarters by an average of 24.6%.
• Analyst Upgrades:
  • Next-year EPS estimates have been revised upward by 10.7% in the past three months.
  • Revenue forecasts for next year have been raised by 67.7%, reflecting strong confidence.

Technical Outlook

According to ChartMill’s technical report, VERV has:

• A Technical Rating of 9/10, reflecting strong bullish trends.
• A Setup Rating of 6/10, suggesting a consolidation phase with potential for a breakout.
• Key support at $11.12 and resistance near $11.22–$11.39.

For a deeper analysis, review the full technical report here.

Our High Growth Momentum + Trend Template screener lists more stocks with similar growth and technical strength.

Disclaimer

This is not investment advice. Always conduct your own research before making trading decisions.